Amgen (AMGN) EBIT Margin (2009 - 2026)

Amgen (AMGN) has reported EBIT Margin for 18 consecutive years, with 30.94% the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT Margin rose 1648.0% year-over-year to 30.94%; the TTM figure through Mar 2026 stood at 28.39% (up 658.0% YoY), while the FY2025 annual figure was 24.71%, up 299.0% from the prior year.
• EBIT Margin came in at 30.94% for Q1 2026 at Amgen, up from 27.57% in the prior quarter.
• The five-year high for EBIT Margin was 485.84% in Q4 2022, with the low at 13.31% in Q1 2024.
• Average EBIT Margin over 5 years is 54.56%, with a median of 28.94% recorded in 2025.
• Across the five-year window, EBIT Margin surged 45218 bps in 2022 and sank 47033 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 485.84% in 2022, then sank by 97 bps to 15.51% in 2023, then surged by 64 bps to 25.43% in 2024, then gained by 8 bps to 27.57% in 2025, then rose by 12 bps to 30.94% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 30.94%, 27.57%, and 26.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.